Condition: Primary Sclerosing Cholangitis (PSC) · Sponsor: LISCure Biosciences
The study is designed to assess the safety and efficacy of LB-P8 in patients with primary sclerosing cholangitis.
This description comes directly from the study's public registry record.
LISCure Biosciences Clinical Trials · +82317061710 · clinical@liscure.bio
Always discuss trial participation with your own doctor first.
| University of California Davis | Sacramento, California, United States | Not Yet Recruiting |
| UCHealth University of Colorado Hospital | Aurora, Colorado, United States | Not Yet Recruiting |
| University Of Iowa Hospitals And Clinics | Iowa City, Iowa, United States | Recruiting |
| Mercy Medical Center | Baltimore, Maryland, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Not Yet Recruiting |
| The Vanderbilt Clinic | Nashville, Tennessee, United States | Recruiting |
| Liver institute Northwest | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06699121